1
|
Abstract
"There's plenty of room at the bottom" (Richard Feynman, 1959): an invitation for (metalla)carboranes to enter the (new) field of nanomedicine. For two decades, the number of publications on boron cluster compounds designed for potential applications in medicine has been constantly increasing. Hundreds of compounds have been screened in vitro or in vivo for a variety of biological activities (chemotherapeutics, radiotherapeutics, antiviral, etc.), and some have shown rather promising potential for further development. However, until now, no boron cluster compounds have made it to the clinic, and even clinical trials have been very sparse. This review introduces a new perspective in the field of medicinal boron chemistry, namely that boron-based drugs should be regarded as nanomedicine platforms, due to their peculiar self-assembly behaviour in aqueous solutions, and treated as such. Examples for boron-based 12- and 11-vertex clusters and appropriate comparative studies from medicinal (in)organic chemistry and nanomedicine, highlighting similarities, differences and gaps in physicochemical and biological characterisation methods, are provided to encourage medicinal boron chemists to fill in the gaps between chemistry laboratory and real applications in living systems by employing bioanalytical and biophysical methods for characterising and controlling the aggregation behaviour of the clusters in solution.
Collapse
Affiliation(s)
- Marta Gozzi
- Institute of Inorganic ChemistryFaculty of Chemistry and MineralogyLeipzig UniversityJohannisallee 2904103LeipzigGermany
- Institute of Analytical ChemistryFaculty of Chemistry and MineralogyLeipzig UniversityLinnéstr. 304103LeipzigGermany
- Institute of Medicinal Physics and BiophysicsFaculty of MedicineLeipzig UniversityHärtelstr. 16–1804107LeipzigGermany
| | - Benedikt Schwarze
- Institute of Medicinal Physics and BiophysicsFaculty of MedicineLeipzig UniversityHärtelstr. 16–1804107LeipzigGermany
| | - Evamarie Hey‐Hawkins
- Institute of Inorganic ChemistryFaculty of Chemistry and MineralogyLeipzig UniversityJohannisallee 2904103LeipzigGermany
| |
Collapse
|
2
|
Yanagie H, Yanagawa M, Higuchi T, Mizumachi R, Fujihara M, Morishita Y, Sakurai Y, Mouri K, Dewi N, Nonaka Y, Shinohara A, Matsukawa T, Kubota A, Yokoyama K, Suzuki M, Masunaga SI, Sakurai Y, Tanaka H, Ono K, Yamauchi H, Ono M, Nakajima J, Higashi S, Takahashi H. Single-dose toxicity study by intra-arterial injection of 10BSH entrapped water-in-oil-in-water emulsion for boron neutron capture therapy to hepatocellular carcinoma. Appl Radiat Isot 2020; 163:109202. [PMID: 32561043 DOI: 10.1016/j.apradiso.2020.109202] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Revised: 01/20/2020] [Accepted: 04/21/2020] [Indexed: 10/24/2022]
Abstract
We developed a mixing medical device by attaching Shirasu porous glass Millipore membrane to prepare water-in-oil-in-water (WOW) emulsion in a shorter time to be applied as 10B-entrapped WOW emulsion for hepatocellular carcinoma (HCC) treatment. Single-dose toxicity studies by intra-arterial injection of 10BSH-entrapped WOW were performed in rabbits and pig, and no side effects were observed. We hope to proceed to the preclinical and clinical studies for further evaluation of 10B compound as multidisciplinary treatments for HCC.
Collapse
Affiliation(s)
- Hironobu Yanagie
- Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, 113-8656, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Research Institute of Healthy Living, Niigata University of Pharmacy & Applied Life Sciences, Niigata, 956-8603, Japan.
| | - Masashi Yanagawa
- Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, 080-8555, Japan
| | - Tsuyoshi Higuchi
- Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, 869-0425, Japan
| | - Ryouji Mizumachi
- Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, 869-0425, Japan
| | | | - Yasuyuki Morishita
- Department of Human & Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan
| | - Yuriko Sakurai
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Research Institute of Healthy Living, Niigata University of Pharmacy & Applied Life Sciences, Niigata, 956-8603, Japan
| | - Kikue Mouri
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Research Institute of Healthy Living, Niigata University of Pharmacy & Applied Life Sciences, Niigata, 956-8603, Japan
| | - Novriana Dewi
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Research Institute of Healthy Living, Niigata University of Pharmacy & Applied Life Sciences, Niigata, 956-8603, Japan
| | - Yasumasa Nonaka
- Department of Surgery, Keiai-kai Hoyo Hospital, Iwate, 028-3111, Japan
| | - Atsuko Shinohara
- Department of Humanities, The Graduate School of Seisen University, Tokyo, 141-8642, Japan; Department of Hygiene, Faculty of Medicine, Juntendo University, Tokyo, 113-8421, Japan
| | - Takehisa Matsukawa
- Department of Hygiene, Faculty of Medicine, Juntendo University, Tokyo, 113-8421, Japan
| | - Ayano Kubota
- Department of Hygiene, Faculty of Medicine, Juntendo University, Tokyo, 113-8421, Japan
| | - Kazuhito Yokoyama
- Department of Hygiene, Faculty of Medicine, Juntendo University, Tokyo, 113-8421, Japan
| | - Minoru Suzuki
- Kyoto Univ Institute for Integrated Radiation & Nuclear Science, Osaka, 590-0494, Japan
| | - Shin-Ichiro Masunaga
- Kyoto Univ Institute for Integrated Radiation & Nuclear Science, Osaka, 590-0494, Japan
| | - Yohinori Sakurai
- Kyoto Univ Institute for Integrated Radiation & Nuclear Science, Osaka, 590-0494, Japan
| | - Hiroki Tanaka
- Kyoto Univ Institute for Integrated Radiation & Nuclear Science, Osaka, 590-0494, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College, Osaka, 569-8686, Japan
| | - Haruo Yamauchi
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Department of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, 113-8655, Japan
| | - Minoru Ono
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Department of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, 113-8655, Japan
| | - Jun Nakajima
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan; Department of Pulmonary Surgery, The University of Tokyo Hospital, Tokyo, 113-8655, Japan
| | - Shushi Higashi
- Department of Surgery, Kojin-kai Medicalcity East Hospital, Miyazaki, 885-0035, Japan
| | - Hiroyuki Takahashi
- Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, 113-8656, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, 113-8655, Japan
| |
Collapse
|
3
|
|
4
|
Pulagam KR, Gona KB, Gómez-Vallejo V, Meijer J, Zilberfain C, Estrela-Lopis I, Baz Z, Cossío U, Llop J. Gold Nanoparticles as Boron Carriers for Boron Neutron Capture Therapy: Synthesis, Radiolabelling and In vivo Evaluation. Molecules 2019; 24:E3609. [PMID: 31591329 PMCID: PMC6804187 DOI: 10.3390/molecules24193609] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 10/01/2019] [Indexed: 02/07/2023] Open
Abstract
Background: Boron Neutron Capture Therapy (BNCT) is a binary approach to cancer therapy that requires accumulation of boron atoms preferentially in tumour cells. This can be achieved by using nanoparticles as boron carriers and taking advantage of the enhanced permeability and retention (EPR) effect. Here, we present the preparation and characterization of size and shape-tuned gold NPs (AuNPs) stabilised with polyethylene glycol (PEG) and functionalized with the boron-rich anion cobalt bis(dicarbollide), commonly known as COSAN. The resulting NPs were radiolabelled with 124I both at the core and the shell, and were evaluated in vivo in a mouse model of human fibrosarcoma (HT1080 cells) using positron emission tomography (PET). Methods: The thiolated COSAN derivatives for subsequent attachment to the gold surface were synthesized by reaction of COSAN with tetrahydropyran (THP) followed by ring opening using potassium thioacetate (KSAc). Iodination on one of the boron atoms of the cluster was also carried out to enable subsequent radiolabelling of the boron cage. AuNPs grafted with mPEG-SH (5 Kda) and thiolated COSAN were prepared by ligand displacement. Radiolabelling was carried out both at the shell (isotopic exchange) and at the core (anionic absorption) of the NPs using 124I to enable PET imaging. Results: Stable gold nanoparticles simultaneously functionalised with PEG and COSAN (PEG-AuNPs@[4]-) with hydrodynamic diameter of 37.8 ± 0.5 nm, core diameter of 19.2 ± 1.4 nm and ξ-potential of -18.0 ± 0.7 mV were obtained. The presence of the COSAN on the surface of the NPs was confirmed by Raman Spectroscopy and UV-Vis spectrophotometry. PEG-AuNPs@[4]- could be efficiently labelled with 124I both at the core and the shell. Biodistribution studies in a xenograft mouse model of human fibrosarcoma showed major accumulation in liver, lungs and spleen, and poor accumulation in the tumour. The dual labelling approach confirmed the in vivo stability of the PEG-AuNPs@[4]-. Conclusions: PEG stabilized, COSAN-functionalised AuNPs could be synthesized, radiolabelled and evaluated in vivo using PET. The low tumour accumulation in the animal model assayed points to the need of tuning the size and geometry of the gold core for future studies.
Collapse
Affiliation(s)
- Krishna R Pulagam
- Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, 20014 San Sebastian, Spain.
| | - Kiran B Gona
- Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, 20014 San Sebastian, Spain.
- Cardiovascular Molecular Imaging Laboratory, Section of Cardiovascular Medicine and Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511, USA.
- Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA.
| | | | - Jan Meijer
- Institute of Medical Physics and Biophysics, Leipzig University, Härtelstrasse 16-18, 04107 Leipzig, Germany.
| | - Carolin Zilberfain
- Felix Bloch Institute for Solid State Physics, Leipzig University, Linnéstraße 5, 04103 Leipzig, Germany.
| | - Irina Estrela-Lopis
- Felix Bloch Institute for Solid State Physics, Leipzig University, Linnéstraße 5, 04103 Leipzig, Germany.
| | - Zuriñe Baz
- Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, 20014 San Sebastian, Spain.
| | - Unai Cossío
- Radioimaging and Image Analysis Platform, CIC biomaGUNE, 20014 San Sebastian, Spain.
| | - Jordi Llop
- Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, 20014 San Sebastian, Spain.
- Centro de Investigación Biomédica en red Enfermedades Respiratorias-CIBERES, 28029 Madrid, Spain.
| |
Collapse
|
5
|
Yanagie H, Dewi N, Higashi S, Ikushima I, Seguchi K, Mizumachi R, Murata Y, Morishita Y, Shinohara A, Mikado S, Yasuda N, Fujihara M, Sakurai Y, Mouri K, Yanagawa M, Iizuka T, Suzuki M, Sakurai Y, Masunaga SI, Tanaka H, Matsukawa T, Yokoyama K, Fujino T, Ogura K, Nonaka Y, Sugiyama H, Kajiyama T, Yui S, Nishimura R, Ono K, Takamoto S, Nakajima J, Ono M, Eriguchi M, Hasumi K, Takahashi H. Selective boron delivery by intra-arterial injection of BSH-WOW emulsion in hepatic cancer model for neutron capture therapy. Br J Radiol 2017; 90:20170004. [PMID: 28406315 DOI: 10.1259/bjr.20170004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE Boron neutron-capture therapy (BNCT) has been used to inhibit the growth of various types of cancers. In this study, we developed a 10BSH-entrapped water-in-oil-in-water (WOW) emulsion, evaluated it as a selective boron carrier for the possible application of BNCT in hepatocellular carcinoma treatment. METHODS We prepared the 10BSH-entrapped WOW emulsion using double emulsification technique and then evaluated the delivery efficacy by performing biodistribution experiment on VX-2 rabbit hepatic tumour model with comparison to iodized poppy-seed oil mix conventional emulsion. Neutron irradiation was carried out at Kyoto University Research Reactor with an average thermal neutron fluence of 5 × 1012 n cm-2. Morphological and pathological analyses were performed on Day 14 after neutron irradiation. RESULTS Biodistribution results have revealed that 10B atoms delivery with WOW emulsion was superior compared with those using iodized poppy-seed oil conventional emulsion. There was no dissemination in abdomen or lung metastasis observed after neutron irradiation in the groups treated with 10BSH-entrapped WOW emulsion, whereas many tumour nodules were recognized in the liver, abdominal cavity, peritoneum and bilateral lobes of the lung in the non-injected group. CONCLUSION Tumour growth suppression and cancer-cell-killing effect was observed from the morphological and pathological analyses of the 10BSH-entrapped WOW emulsion-injected group, indicating its feasibility to be applied as a novel intra-arterial boron carrier for BNCT. Advances in knowledge: The results of the current study have shown that entrapped 10BSH has the potential to increase the range of therapies available for hepatocellular carcinoma which is considered to be one of the most difficult tumours to cure.
Collapse
Affiliation(s)
- Hironobu Yanagie
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan.,2 Department of Nuclear Engineering and Management, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.,3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan
| | - Novriana Dewi
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan.,3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan
| | - Syushi Higashi
- 4 Department of Surgery, Kojinkai Medical City East Hospital, Miyazaki, Japan
| | - Ichiro Ikushima
- 5 Department of Radiology, Miyakonojyo Metropolitan Hospital, Miyazaki, Japan
| | - Koji Seguchi
- 4 Department of Surgery, Kojinkai Medical City East Hospital, Miyazaki, Japan
| | - Ryoji Mizumachi
- 6 Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Co. Ltd, Kumamoto, Japan
| | - Yuji Murata
- 6 Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Co. Ltd, Kumamoto, Japan
| | - Yasuyuki Morishita
- 7 Department of Human and Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Atsuko Shinohara
- 8 Department of Humanities, The Graduate School of Seisen University, Tokyo, Japan
| | - Shoji Mikado
- 9 Department of Physics, College of Industrial Technology, Nihon University, Chiba, Japan
| | - Nakahiro Yasuda
- 10 Research Institute of Nuclear Engineering, University of Fukui, Fukui, Japan
| | | | - Yuriko Sakurai
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan.,3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan
| | - Kikue Mouri
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan.,3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan
| | - Masashi Yanagawa
- 12 Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan
| | - Tomoya Iizuka
- 13 Department of Veterinary Surgery, The University of Tokyo Veterinary Hospital, Tokyo, Japan
| | - Minoru Suzuki
- 14 Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | | | - Hiroki Tanaka
- 14 Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Takehisa Matsukawa
- 15 Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Kazuhito Yokoyama
- 15 Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Takashi Fujino
- 16 Department of Pathological Diagnosis, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan
| | - Koichi Ogura
- 9 Department of Physics, College of Industrial Technology, Nihon University, Chiba, Japan
| | - Yasumasa Nonaka
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan
| | - Hirotaka Sugiyama
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan
| | - Tetsuya Kajiyama
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan
| | - Sho Yui
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan
| | - Ryohei Nishimura
- 13 Department of Veterinary Surgery, The University of Tokyo Veterinary Hospital, Tokyo, Japan
| | - Koji Ono
- 14 Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Sinichi Takamoto
- 17 Department of Cardiac Surgery, Mitsui Memorial Hospital, Tokyo, Japan
| | - Jun Nakajima
- 3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.,18 Department of Pulmonary Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Minoru Ono
- 3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.,19 Department of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Masazumi Eriguchi
- 1 Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, Tokyo, Japan.,20 Department of Surgery, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | | | - Hiroyuki Takahashi
- 2 Department of Nuclear Engineering and Management, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.,3 Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan
| |
Collapse
|
6
|
Mi P, Yanagie H, Dewi N, Yen HC, Liu X, Suzuki M, Sakurai Y, Ono K, Takahashi H, Cabral H, Kataoka K, Nishiyama N. Block copolymer-boron cluster conjugate for effective boron neutron capture therapy of solid tumors. J Control Release 2017; 254:1-9. [DOI: 10.1016/j.jconrel.2017.03.036] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 01/18/2017] [Accepted: 03/19/2017] [Indexed: 01/15/2023]
|
7
|
Wang J, Wu W, Jiang X. Nanoscaled boron-containing delivery systems and therapeutic agents for cancer treatment. Nanomedicine (Lond) 2015; 10:1149-63. [DOI: 10.2217/nnm.14.213] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Significant efforts have recently been made to develop nanoscaled boron-containing delivery systems for improving drug delivery in cancer therapy. On one hand, borate ester chemistry has shown importance in ligand-mediated tumor targeting owing to the recognition ability of boronic acid to polyol residues in cell membranes. In particular, the phenylboronic acid-functionalized nanocarriers for specific targeting to sialic acid groups which are overexpressed on tumor cells have made great achievements. On the other hand, nanoscaled boron neutron capture therapy agents show growing potential in efficiently transporting boron to tumor. The current review outlines the recent developments in the application of borate ester chemistry in tumor targeting by nanoparticles, then summarizes recent work on the development of boron-based nanomaterials as boron neutron capture therapy agents.
Collapse
Affiliation(s)
- Jing Wang
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, People's Republic of China
| | - Wei Wu
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, People's Republic of China
| | - Xiqun Jiang
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, People's Republic of China
| |
Collapse
|
8
|
WITHDRAWN: Selective enhancement of boron accumulation in tumours with intra-arterial administration of boron-entrapped water-in-oil-in-water emulsion as a novel boron carrier in VX-2 rabbit hepatic cancer model for neutron capture therapy. Pharmacotherapy 2015. [DOI: 10.1016/j.biopha.2014.12.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
9
|
Yanagie H, Higashi S, Seguchi K, Ikushima I, Fujihara M, Nonaka Y, Oyama K, Maruyama S, Hatae R, Suzuki M, Masunaga SI, Kinashi T, Sakurai Y, Tanaka H, Kondo N, Narabayashi M, Kajiyama T, Maruhashi A, Ono K, Nakajima J, Ono M, Takahashi H, Eriguchi M. Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion. Appl Radiat Isot 2014; 88:32-7. [PMID: 24559940 DOI: 10.1016/j.apradiso.2014.01.014] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Revised: 01/16/2014] [Accepted: 01/16/2014] [Indexed: 10/25/2022]
Abstract
A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.
Collapse
Affiliation(s)
- Hironobu Yanagie
- Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; Department of Nuclear Engineering & Management, Graduate School of Engineering, The University of Tokyo, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan.
| | - Syushi Higashi
- Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan
| | - Koji Seguchi
- Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan
| | - Ichiro Ikushima
- Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; Kyushu Medical & Industrial Sources Foundation, Miyazaki, Japan; Department of Radiology, Miyakonojyo Metropolitan Hospital, Miyazaki, Japan
| | | | | | - Kazuyuki Oyama
- Department of Radiology, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Syoji Maruyama
- Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Ryo Hatae
- Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Minoru Suzuki
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | - Tomoko Kinashi
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | - Hiroki Tanaka
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Natsuko Kondo
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | - Tetsuya Kajiyama
- Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
| | | | - Koji Ono
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Jun Nakajima
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan; Department of Respiratory Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Minoru Ono
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan; Department of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Hiroyuki Takahashi
- Department of Nuclear Engineering & Management, Graduate School of Engineering, The University of Tokyo, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan
| | - Masazumi Eriguchi
- Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| |
Collapse
|
10
|
Efficacy of HGF carried by ultrasound microbubble-cationic nano-liposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. Clin Res Hepatol Gastroenterol 2013; 37:602-7. [PMID: 24012221 DOI: 10.1016/j.clinre.2013.05.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2012] [Revised: 04/23/2013] [Accepted: 05/14/2013] [Indexed: 02/04/2023]
Abstract
Hepatic fibrosis is a major consequence of liver aggression. Finding novel ways for counteracting this damaging process, and for evaluating fibrosis with a non-invasive imaging approach, represent important therapeutic and diagnostic challenges. Hepatocyte growth factor (HGF) is an anti-fibrosis cell growth factor that induces apoptosis in activated hepatic stellate cells, reduces excessive collagen deposition, and stimulates hepatocyte regeneration. Thus, using HGF in gene therapy against liver fibrosis is an attractive approach. The aims of the present study were: (i) to explore the efficacy of treating liver fibrosis using HGF expression vector carried by a novel ultrasound microbubble delivery system; (ii) to explore the diagnostic interest of diffusion-weighted MRI (DWI-MRI) in evaluating liver fibrosis. We established a rat model of hepatic fibrosis. The rats were administered HGF linked to novel ultrasound micro-bubbles. Progression of hepatic fibrosis was evaluated by histopathology, hydroxyproline content, and DWI-MRI to determine the apparent diffusion coefficient (ADC). Our targeted gene therapy produced a significant anti-fibrosis effect, as shown by liver histology and significant reduction of hydroxyproline content. Moreover, using DWI-MRI, the b value (diffusion gradient factor) was equal to 300s/mm(2), and the ADC values significantly decreased as the severity of hepatic fibrosis increased. Using this methodology, F0-F2 could be distinguished from F3 and F4 (P<0.01). This is the first in vivo report of using an ultrasound microbubble-cationic nano-liposome complex for gene delivery. The data indicate that, this approach is efficient to counteract the fibrosis process. DWI-MRI appears a promising imaging technique for evaluating liver fibrosis.
Collapse
|
11
|
Applications and perspectives of boron-enriched nanocomposites in cancer therapy. Future Med Chem 2013; 5:705-14. [PMID: 23617432 DOI: 10.4155/fmc.13.47] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Recently, boron compounds have attracted increasing attention both in academic laboratories and in the pharmaceutical industry. Boron, in particular the (10)B isotope, has the unique capability of absorbing a slow neutron to initiate a nuclear reaction with release of energetic particles such as α- and Li-particles, which is not observed in its carbon analogues. The nuclear capture reaction concept has been adopted in radiation therapy and used in boron neutron capture therapy (BNCT). BNCT is a potentially promising treatment for malignant brain tumors as well as other cancers, despite the limitation of a scarcity of neutron sources. There is the need in advanced research centers to construct high boron-containing composites as BNCT agents and develop more efficient drug carriers. This review discusses recent works on the development of boron-based therapeutic nanomaterials as BNCT agents.
Collapse
|
12
|
Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent. Biomed Pharmacother 2012; 67:451-7. [PMID: 23743325 DOI: 10.1016/j.biopha.2012.11.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2012] [Accepted: 11/23/2012] [Indexed: 11/21/2022] Open
Abstract
Neutron capture therapy (NCT) is a promising non-invasive cancer therapy approach and some recent NCT research has focused on using compounds containing gadolinium as an alternative to currently used boron-10 considering several advantages that gadolinium offers compared to those of boron. In this study, we evaluated gadolinium-entrapped liposome compound as neutron capture therapy agent by in vivo experiment on colon-26 tumor-bearing mice. Gadolinium compound were injected intravenously via tail vein and allowed to accumulate into tumor site. Tumor samples were taken for quantitative analysis by ICP-MS at 2, 12, and 24 h after gadolinium compound injection. Highest gadolinium concentration was observed at about 2 h after gadolinium compound injection with an average of 40.3 μg/g of wet tumor tissue. We performed neutron irradiation at JRR-4 reactor facility of Japan Atomic Energy Research Institute in Tokaimura with average neutron fluence of 2×10¹² n/cm². The experimental results showed that the tumor growth suppression of gadolinium-injected irradiated group was revealed until about four times higher compared to the control group, and no significant weight loss were observed after treatment suggesting low systemic toxicity of this compound. The gadolinium-entrapped liposome will become one of the candidates for Gd delivery system on NCT.
Collapse
|
13
|
Lee JD, Cho SJ, Kim SH, Chai GY, Lee CH. New Types of o-Carboranyl Heterocyclic Compounds: Synthesis and Characterization of Morpholino and Di(methoxyethyl)amino Substituted 1,3,5-Triazine Derivatives. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.9.3136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
14
|
Sumitani S, Oishi M, Yaguchi T, Murotani H, Horiguchi Y, Suzuki M, Ono K, Yanagie H, Nagasaki Y. Pharmacokinetics of core-polymerized, boron-conjugated micelles designed for boron neutron capture therapy for cancer. Biomaterials 2012; 33:3568-77. [DOI: 10.1016/j.biomaterials.2012.01.039] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Accepted: 01/17/2012] [Indexed: 11/28/2022]
|
15
|
|
16
|
Pietrangeli D, Ristori S, Rosa A, Ricciardi G. Carboranylporphyrazines for anti-cancer therapies: synthesis and physicochemical properties. J PORPHYR PHTHALOCYA 2012. [DOI: 10.1142/s1088424610002574] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The synthesis, the salient physicochemical properties, and liposome insertion of carboranyl-alkylthio-porphyrazines, a new family of potential BNCT agents, are here reviewed together with recent progresses in their metalation and conversion in the water-soluble counterparts.
Collapse
Affiliation(s)
- Daniela Pietrangeli
- Dipartimento di Chimica, Università della Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy
| | - Sandra Ristori
- Dipartimento di Chimica, Università di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino (Fi), Italy
- CSGI, Università di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino (Fi), Italy
| | - Angela Rosa
- Dipartimento di Chimica, Università della Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy
| | - Giampaolo Ricciardi
- Dipartimento di Chimica, Università della Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy
| |
Collapse
|
17
|
Feasibility evaluation of neutron capture therapy for hepatocellular carcinoma using selective enhancement of boron accumulation in tumour with intra-arterial administration of boron-entrapped water-in-oil-in-water emulsion. Appl Radiat Isot 2011; 69:1854-7. [DOI: 10.1016/j.apradiso.2011.04.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Revised: 04/16/2011] [Accepted: 04/18/2011] [Indexed: 11/24/2022]
|
18
|
SUZUKI R, ODA Y, UTOGUCHI N, MARUYAMA K. Development of Ultrasonic Cancer Therapy Using Ultrasound Sensitive Liposome. YAKUGAKU ZASSHI 2010; 130:1665-70. [DOI: 10.1248/yakushi.130.1665] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Ryo SUZUKI
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University
| | - Yusuke ODA
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University
| | - Naoki UTOGUCHI
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University
| | - Kazuo MARUYAMA
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University
| |
Collapse
|
19
|
Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010; 2010. [PMID: 20811605 PMCID: PMC2929518 DOI: 10.1155/2010/953537] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2010] [Accepted: 06/15/2010] [Indexed: 12/18/2022] Open
Abstract
Current progress in nanomedicine has exploited the possibility of designing tumor-targeted nanocarriers being able to deliver radionuclide payloads in a site or molecular selective manner to improve the efficacy and safety of cancer imaging and therapy. Radionuclides of auger electron-, α-, β-, and γ-radiation emitters have been surface-bioconjugated or after-loaded in nanoparticles to improve the efficacy and reduce the toxicity of cancer imaging and therapy in preclinical and clinical studies. This article provides a brief overview of current status of applications, advantages, problems, up-to-date research and development, and future prospects of nanotargeted radionuclides in cancer nuclear imaging and radiotherapy. Passive and active nanotargeting delivery of radionuclides with illustrating examples for tumor imaging and therapy are reviewed and summarized. Research on combing different modes of selective delivery of radionuclides through nanocarriers targeted delivery for tumor imaging and therapy offers the new possibility of large increases in cancer diagnostic efficacy and therapeutic index. However, further efforts and challenges in preclinical and clinical efficacy and toxicity studies are required to translate those advanced technologies to the clinical applications for cancer patients.
Collapse
|
20
|
Yanagië H, Ogata A, Sugiyama H, Eriguchi M, Takamoto S, Takahashi H. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 2008; 5:427-43. [PMID: 18426384 DOI: 10.1517/17425247.5.4.427] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Tumor cell destruction in boron neutron capture therapy (BNCT) is due to the nuclear reaction between (10)B and thermal neutrons ((10)B + (1)n --> (7)Li + (4)He (alpha) + 2.31 MeV (93.7 %)/2.79 MeV (6.3 %)). The resulting lithium ions and alphaparticles are high linear energy transfer (LET) particles which give a high biological effect. Their short range in tissue (5 - 9 mum) restricts radiation damage to those cells in which boron atoms are located at the time of neutron irradiation. BNCT has been applied clinically for the treatment of malignant brain tumors, malignant melanoma, head and neck cancer and hepatoma. Sodium mercaptoundecahydro-dodecaborate (Na(2)(10)B(12)H(11)SH: BSH) and borono-phenylalanine ((10)BPA) are currently being used in clinical treatments. These low molecule compounds are easily cleared from cancer cells and blood, so high accumulation and selective delivery of boron compounds into tumor tissues and cancer cells are most important to achieve effective BNCT and to avoid damage to adjacent healthy cells. OBJECTIVE In order to achieve the selective delivery of boron atoms to cancer cells, a drug delivery system (DDS) is an attractive intelligent technology for targeting and controlled release of drugs. METHODS We performed literature searches related to boron delivery systems in vitro and in vivo. RESULTS We describe several DDS technologies for boron delivery to cancer tissues and cancer cells from the past to current status. We are convinced that it will be possible to use liposomes, monoclonal antibodies and WOW emulsions as boron delivery systems for BNCT clinically in accordance with the preparation of good commercial product (GCP) grade materials.
Collapse
Affiliation(s)
- Hironobu Yanagië
- University of Tokyo, Department of Nuclear Engineering and Management, Graduate School of Engineering, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
21
|
Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60:1329-46. [PMID: 18562040 DOI: 10.1016/j.addr.2008.04.013] [Citation(s) in RCA: 199] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2007] [Accepted: 04/16/2008] [Indexed: 01/30/2023]
Abstract
The recent developments of nuclear medicine in oncology have involved numerous investigations of novel specific tumor-targeting radiopharmaceuticals as a major area of interest for both cancer imaging and therapy. The current progress in pharmaceutical nanotechnology field has been exploited in the design of tumor-targeting nanoscale and microscale carriers being able to deliver radionuclides in a selective manner to improve the outcome of cancer diagnosis and treatment. These carriers include chiefly, among others, liposomes, microparticles, nanoparticles, micelles, dendrimers and hydrogels. Furthermore, combining the more recent nuclear imaging multimodalities which provide high sensitivity and anatomical resolution such as PET/CT (positron emission tomography/computed tomography) and SPECT/CT (combined single photon emission computed tomography/computed tomography system) with the use of these specific tumor-targeting carriers constitutes a promising rally which will, hopefully in the near future, allow for earlier tumor detection, better treatment planning and more powerful therapy. In this review, we highlight the use, limitations, advantages and possible improvements of different nano- and microcarriers as potential vehicles for radionuclides delivery in cancer nuclear imaging and radiotherapy.
Collapse
Affiliation(s)
- Misara Hamoudeh
- Université de Lyon, 69622, France, Université Lyon1, CNRS, UMR 5007, LAGEP, Pharmacotechnical department, ISPB facuté de Pharmacie
| | | | | | | |
Collapse
|
22
|
Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models. Br J Cancer 2007; 98:399-409. [PMID: 18087283 PMCID: PMC2361451 DOI: 10.1038/sj.bjc.6604133] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Polyoxomolybdates (PMs) as discrete molybdenum-oxide cluster anions have been investigated in the course of study of their medical applications. Here, we show the significant antitumour potency of the polyoxomolybdate [Me(3)NH](6)[H(2)Mo(V)(12)O(28)(OH)(12)(Mo(VI)O(3))(4)].2H(2)O (PM-17), which is a photo-reduced compound of [NH(3)Pr(i)](6)[Mo(7)O(24)].3H(2)O. The effect of PM-17 on the growth of cancer cell lines and xenografts was assessed by a cell viability test and analysis of tumour expansion rate. Morphological analysis was carried out by Hoechst staining, flow-cytometric analysis of Annexin V staining, terminal deoxynucleotidyl transferase-mediated 'nick-end' labelling staining, and electron-microscopic analysis. Activation of autophagy was detected by western blotting and fluorescence-microscopic analysis of the localisation of GFP-LC3 in transfected tumour cells. PM-17 inhibited the growth of human pancreatic cancer (AsPC-1) xenografts in a nude mice model, and induced morphological alterations in tumour cells. Correspondingly, PM-17 repressed the proliferation of AsPC-1 cells and human gastric cancer cells (MKN45) depending on the dose in vitro. We observed apoptotic patterns as the formation of apoptotic small bodies and translocation of phosphatidylserine by Hoechst staining and flow-cytometric analysis following Annexin V staining, and in parallel, autophagic conformation by the formulation of autophagosomes and localisation of GFP-LC3 by electron- and fluorescence-microscopic analysis.
Collapse
|
23
|
Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Maruyama K. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm 2007; 354:49-55. [PMID: 18082343 DOI: 10.1016/j.ijpharm.2007.10.034] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2007] [Revised: 10/19/2007] [Accepted: 10/22/2007] [Indexed: 10/22/2022]
Abstract
From the viewpoint of safety, non-viral vector systems represent an attractive gene delivery system for gene therapy. However, the transfection efficiency of non-viral vectors in vivo is generally very low. Previously, it was reported that microbubbles, utilized as imaging agents for diagnostic echocardiography, could promote gene delivery into cells when combined with ultrasound exposure. We therefore developed novel liposomal bubbles (Bubble liposomes) containing the lipid nanobubbles of perfluoropropane which is used as ultrasound imaging agent. These Bubble liposomes were smaller in diameter than conventional microbubbles and induced cavitation upon exposure to ultrasound. These results suggested that cavitation of these Bubble liposomes could be an efficient approach for delivering plasmid DNA into cells. In addition, in in vivo gene delivery, the combination of Bubble liposomes and ultrasound provided more effective gene delivery than conventional lipofection methods, further suggesting that Bubble liposomes could be effective as a non-viral vector system in in vivo gene delivery. In this review, we discuss the characteristics of Bubble liposomes and their potential utility as a gene delivery tool in vitro and in vivo.
Collapse
Affiliation(s)
- Ryo Suzuki
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University, 1091-1 Suwarashi, Sagamiko, Sagamihara, Kanagawa 229-0195, Japan
| | | | | | | | | |
Collapse
|
24
|
Yanagie H, Sakurai Y, Ogura K, Kobayashi T, Furuya Y, Sugiyama H, Kobayashi H, Ono K, Nakagawa K, Takahashi H, Nakazawa M, Eriguchi M. Evaluation of neutron dosimetry on pancreatic cancer phantom model for application of intraoperative boron neutron-capture therapy. Biomed Pharmacother 2007; 61:505-14. [PMID: 17614250 DOI: 10.1016/j.biopha.2006.12.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2006] [Accepted: 12/12/2006] [Indexed: 11/30/2022] Open
Abstract
Pancreatic cancer is one of the most difficult neoplasms to cure and there is a need for new combinated therapy. If sufficient boron compound can be targeted accurate to the tumour, Boron Neutron-Capture Therapy (BNCT) can be applied to pancreatic cancer. We administrated BNCT to a cancer with pancreatic cancer patient using intraoperative irradiation. In this study, we performed preliminary dosimetry of a phantom model of the abdominal cavity. The flux of 8>x10(7)n/cm(2)/s (0.1 ratio) was 4.5 cm in depth from the surface in the case of simple irradiation, and the field of thermal neutrons was spread as 13 cm and 11.5 cm were usage of Void and Void with LiF collimation, respectively in thermal (OO-0011) mode. In the case of epithermal (CO-0000) mode, epithermal and fast components are four times higher at the surface level. In the case of mixed beam (OO-0000) mode, thermal neutron flux was the same as thermal neutron mode at a depth of 10 cm, but the gamma-ray component was two times higher than that of thermal neutron mode. With the use of Void and LiF collimation, thermal neutrons were selectively applied to the tumour combined with the CT-imaging of the cancer patient. This means that we could irradiate the tumour selectively and safely as possible, reducing the effects on neighboring healthy tissues. High resolution whole body dosimetry will be necessary to extend the application of BNCT to pancreatic cancer.
Collapse
Affiliation(s)
- Hironobu Yanagie
- Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Sawamura K, Tanaka K, Namai E, Oda Y, Matsumura Y, Maruyama K. Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J Control Release 2007; 125:137-44. [PMID: 18035442 DOI: 10.1016/j.jconrel.2007.08.025] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2006] [Revised: 08/13/2007] [Accepted: 08/19/2007] [Indexed: 10/22/2022]
Abstract
Bubble liposomes (liposomes which entrap an ultrasound imaging gas) may constitute a unique system for delivering various molecules efficiently into mammalian cells in vitro. In this study, Bubble liposomes were compared with cationic lipid (CL)-DNA complexes as potential gene delivery carriers into tumor in vivo. The delivery of genes by Bubble liposomes depended on the intensity of the applied ultrasound. Transfection efficiency plateaued at 0.7 W/cm(2) ultrasound intensity. Bubble liposomes efficiently transferred genes into cultured cells even when the cells were exposed to ultrasound for only 1 s. In addition, Bubble liposomes could introduce the luciferase gene more effectively than CL-DNA complexes into mouse ascites tumor cells and solid tumor tissue. We conclude that the combination of Bubble liposomes and ultrasound is a minimally-invasive and tumor specific gene transfer method in vivo.
Collapse
Affiliation(s)
- Ryo Suzuki
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University, 1091-1 Suwarashi, Sagamiko, Sagamihara, Kanagawa 229-0195, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Suzuki R, Takizawa T, Negishi Y, Hagisawa K, Tanaka K, Sawamura K, Utoguchi N, Nishioka T, Maruyama K. Gene delivery by combination of novel liposomal bubbles with perfluoropropane and ultrasound. J Control Release 2006; 117:130-6. [PMID: 17113176 DOI: 10.1016/j.jconrel.2006.09.008] [Citation(s) in RCA: 194] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2006] [Revised: 08/07/2006] [Accepted: 09/14/2006] [Indexed: 12/20/2022]
Abstract
Microbubbles and ultrasound have recently been investigated with a view to improving the transfection efficiency of non-viral gene delivery systems. However, microbubbles are unstable and their targeting ability is insufficient for clinical use. To circumvent these problems, we developed novel polyethyleneglycol (PEG) modified liposomes (Bubble liposomes) containing perfluoropropane, which is an ultrasound imaging gas. Here, we used ultrasound to induce cavitation in Bubble liposomes and then investigated their ability to deliver genes in vitro and in vivo. Bubble liposomes could deliver plasmid DNA to many cell types without cytotoxicity. Additionally, in vivo gene delivery, Bubble liposomes were more effective delivery into femoral artery than lipofection method. Thus, Bubble liposomes might be efficient and novel non-viral tools for gene delivery.
Collapse
Affiliation(s)
- Ryo Suzuki
- Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University, 1091-1 Suwarashi, Sagamiko-cho, Sagamihara, Kanagawa, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Yanagie H, Ogata A, Mitsui S, Hisa T, Yamase T, Eriguchi M. Anticancer activity of polyoxomolybdate. Biomed Pharmacother 2006; 60:349-52. [PMID: 16860529 DOI: 10.1016/j.biopha.2006.06.018] [Citation(s) in RCA: 104] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2006] [Accepted: 02/22/2006] [Indexed: 11/20/2022] Open
Abstract
Anticancer polyoxomolybdates have been investigated for medical application of polyoxometalates as discrete cluster anions of metal oxides. [NH3Pri]6[Mo7O24].3H2O (PM-8) has been recognized as one of significant antitumoral polyoxomolybdates. PM-8 had shown the growth suppression against several tumors, for examples, Co-4, human colon cancer, MX-1, human breast cancer, and OAT, human lung cancer. PM-8 showed the tumor growth suppression for MKN-45 human gastric cancer in tumor bearing mice. PM-8 inhibited the cell growth of AsPC-1 which depended on the dose with showing DNA ladder formation and DNA fragmentation, and positive Hoechst staining indicating apoptosis. The ratio of apoptotic cells on flow cytometry analysis were 35%, and 57% with treatment of PM-8 after 48, and 72 h, respectively. One of the anti-tumor activity of PM-8 result from the activation of apoptotic pathway. It is thought that polyoxomolybdates will be applied as a novel anti-tumor agent especially against cancers which are difficult to be treated clinically.
Collapse
Affiliation(s)
- H Yanagie
- Department of Intellectual Property, Project of Cancer Metastasis Inhibition, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan.
| | | | | | | | | | | |
Collapse
|